Glenmark becomes the First Pharmaceutical Company to launch Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults
‐ Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
‐ This anti-diabetic medication will be marketed under the brand name LOBG.
‐ With this launch, the company aims to improve glycemic levels in uncontrolled diabetics and create a new pathway to treat insulin resistance in India
.‐ Glenmark’s LOBG is priced at approximately INR 10 per tablet, per day.
Mumbai, October, 2022: Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company, became the first to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in adults. Marketed under the brand name LOBG; it contains Lobeglitazone (0.5 mg) and tobe taken once daily under prescription to improve glycemic control in adult diabetic patients. Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes among insulin-resistant diabetic patients.
Glenmark earlier received approval from the Indian drug regulator, Drug Controller General of India, for manufacturing and marketing Lobeglitazone based on a randomized, double-blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older.The results of this trial have shown a faster and improved glycemic control with Lobeglitazone.
On the occasion of the launch, Alok Malik, EVP&Business Head - India Formulations, Glenmark Pharmaceuticals, said,“As per the International Diabetes Federation, diabetes affects 74 million adults in India, of which, around 40% of them seem to be insulin-resistant. As a leading solutions provider in India for the treatment of diabetes, we are proud to introduce LOBG;an innovative and affordable drug, which will help in tackling insulin resistance among adult patients suffering from uncontrolled Type 2 diabetes in the country.”